Innophos Acquires AMT
AMT, a privately held company based in North Salt Lake, Utah, has been manufacturing custom ingredients for the food, beverage, confectionary and nutraceutical industries for more than 20 years. AMT specializes in mineral ingredients essential to the human diet that are manufactured in various forms, including as chelates, to be easily digested (bioactive). Innophos notes AMT is highly complementary to the Kelatron business acquired by Innophos in November 2011. The combined businesses of Kelatron and AMT make Innophos among the leaders in U.S. bioactive mineral ingredients, with annualized revenues approximating $30 million.
Randy Gress, chairman and chief executive officer of Innophos, commented, "The acquisition of AMT represents the second step in our adjacency strategy to expand in product categories closely related to our existing specialty phosphate product line. AMT's strengths are highly complementary to our new bioactive mineral ingredients business platform, providing high quality manufacturing facilities better able to support the future growth expected in this product range. AMT has also been developing new market potential for its products which we expect will bring commercial successes in addition to the expected portfolio synergies of the combined business of AMT and Kelatron, which itself has performed strongly since its acquisition by Innophos last year."
In the transaction, Innophos Inc. purchased for cash 100% of the equity of AMT Labs Inc. and an affiliated real estate company holding all AMT real property, including unused land and buildings to support future expansion. The combined purchase price was $27 million, with $19.5 million being allocated to the AMT purchase and $7.5 million being allocated to the real estate entity. The transaction includes potential for additional consideration contingent upon success in developing new market opportunities. Closing of the purchase occurred upon execution of the definitive agreements effective as of July 17, 2012. The acquisition is expected to be accretive to results in 2012.